The effect of an orally-dosed Caralluma Fimbriata extract on appetite control and body composition in overweight adults.

To examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. A double-blind, randomised, placebo controlled trial to examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. Eighty-three men and women aged between 20 and 50 years of age completed 16 weeks of daily supplementation with either CFE or placebo. Plasma cardiometabolic (lipid profile, glucose, insulin) and satiety (ghrelin, leptin, neuropeptideY) biomarkers, body composition, diet history and gastrointenstinal function were assessed at baseline, weeks 4, 8, 12 and 16. Subjects in the CFE and placebo groups were well matched and predominatly female 93% and 87.5%, with a mean age of 40.9 ± 6.7 and 39.5 ± 7.5 years and body mass index (BMI) of 30.0 ± 3.1 and 30.2 ± 2.9 kg/m2 respectively. There was a significant difference in plasma leptin concentration change between groups at week 16 (p = 0.04), with the placebo group increasing concentration (2.27 ± 4.80 ng/mL) while the CFE group (0.05 ± 4.69 ng/mL) remained the same. At week 16, the CFE group had significantly reduced their calorie intake from baseline compared to the placebo group (245 cal vs 15.8 cal respectively p < 0.01). The CFE group also had a significant reduction in waist circumference of 2.7 cm compared to an increase of 0.3 cm in the placebo group (p = 0.02). A weight increase from baseline was seen in the placebo group that was not observed in the CFE group (1.33 kg weight gain vs 0.37 kg weight loss respectively; p = 0.03). The placebo group also had a significant increase in fat mass, android fat mass, BMI and leptin compared to the CFE group (p = 0.04, 0.02, < 0.01 respectively). CFE was effective at maintaining bodyweight during a non-calorie controlled diet compared to a placebo. The mechanism responsible for this action is requiring further research and could be due to an increase in satiety receptor sensitivity.

Curcumin Improves Delayed Onset Muscle Soreness and Postexercise Lactate Accumulation.

The efficacy of curcumin supplementation is traditionally limited due to its poor bioavailability. Despite this, curcumin has previously been shown to improve biomarkers of muscle damage. The addition of a novel drug delivery system that improves bioavailability could improve exercise recovery. The purpose of this randomized double-blind placebo-controlled study was to assess the effect of curcumin (combined with LipiSperse) when consumed as a drink on exercise recovery in recreationally trained healthy males aged 18-35 yrs. The study included 28 young healthy males with strength training experience. The participants undertook lower limb resistance exercise to exhaustion. Fourteen participants received curcumin dispersed in water pre and postexercise and 14 received a matched placebo drink. Pain (visual analogue scale), thigh circumference (TC), lactate, creatine kinase, lactate dehydrogenase, high sensitivity C-reactive protein, myoglobin, interleukin-6, interleukin-10, and tumor necrosis factor-alpha were assessed pre, postexercise and 1, 2, 3, 24, 48, and 72 h postexercise. There was less appearance of postexercise capillary lactate in the curcumin group compared to placebo (7.4 vs 8.8 mmol/L). The placebo group rated overall muscle pain as higher compared to the curcumin group at 48- and 72-h postexercise. TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise. The results suggest curcumin may facilitate a quicker return to exercise training and/or allow a higher training intensity than a placebo by reducing postexercise pain, modulating inflammatory pathways and reducing lactate accumulation in an exercising population.

Protein supplements: do they alter dietary intakes?

Effects of protein versus mixed macronutrient supplementation on total energy intake (TEI) and protein intake during an ad libitum diet were examined. Trained males undertook two, 2-week dietary interventions which were randomized, double blinded, and separated by 2 weeks. These were high-protein supplementation (HP: 1034.5 kJ energy, 29.6 g protein, 8.7 g fat and 12.3 g CHO) and standard meal supplementation (SM: 1039 kJ energy, 9.9 g protein, 9.5 g fat, and 29.4 g CHO) consumed daily following a week of baseline measures. Eighteen participants finished both interventions and one only completed HP. TEI (mean ± SD) was not different between baseline (11148 ± 3347 kJ) and HP (10705 ± 3143 kJ) nor between baseline and SM (12381 ± 3877 kJ), however, TEI was greater with SM than HP (923 ± 4015 kJ p = .043). Protein intake (%TEI) was greater with HP (22.4 ± 6.2%) than baseline (19.4 ± 5.4%; p = .008) but not SM (20.0 ± 5.0%). No differences in absolute daily protein intake were found. Absolute CHO intake was greater with SM than HP (52.0 ± 89.5 g, p = .006). No differences in fat intake were found. Body mass did not change between baseline (82.7 ± 11.2 kg) and either HP (83.1 ± 11.7 kg) or SM (82.9 ± 11.0 kg). Protein supplementation increases the relative proportion of protein in the diet, but doesn't increase the absolute amount of total protein or energy consumed. Thus some compensation by a reduction in other foods occurs. This is in contrast to a mixed nutrient supplement, which does not alter the proportion of protein consumed but does increase TEI.